Search
Flavoxate
go.drugbank.com/drugs/DB01148ApprovedA drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
Silver sulfadiazine
go.drugbank.com/drugs/DB05245ApprovedInvestigationalVet approvedSilver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Products: DERMOPLATA CREMA AL 1%, SULFADIAZINA CREMA AL 1 %Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292]
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigationalInotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin … [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542]
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.
Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsProducts: Ketamin G.L. 10 mg/ml - Injektions-/Infusionslösung in Ampullen, Ketamin G.L. 50 mg/ml - Injektions-/Infusionslösung in AmpullenNickel sulfate
go.drugbank.com/drugs/DB14180ApprovedNickel sulfate is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingErythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalErythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. … Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with
Products: EPO STADA 2000IU/0.6ml Solution for Injection in a Pre-filled Syringe, EPO STADA 4000IU/0.4ml Solution for Injection in a Pre-filled SyringeMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidCategories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 Substrates with a Narrow Therapeutic IndexSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]